WCN26-8294 WHICH DRUG IS THE GREATER CONCERN FOR RENAL FAILURE IN LUNG CANCER THERAPY – CARBOPLATIN OR PEMETREXED?

Read full text Summarise with VIRAT
Authors: Nidhi Gupta
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

A combination of Pemtrexed (PEM) (anti-folate cytostatic) and Carboplatin (second generation platinum based) has emerged as another acceptable alternative for stage III patients with non-small cell lung carcinoma. The decision to use these drugs is a balance between extending life and managing severe adverse effects.

Fields of Study & Subjects

Chemotherapy-induced organ toxicity mitigation Lung Cancer Diagnosis and Treatment Lung Cancer Treatments and Mutations

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
104175–104175
Publication date
25 March 2026
Language
EN